atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
The Bacillus Calmette-Guérin (BCG) vaccine prevents severe forms of tuberculosis (TB) and is the world’s most widely used vaccine, as well as the oldest vaccine still in use.
Read more here.
Cigna's Evernorth is investing $100 million through 2028 in specialty pharmacy care.
The AI program called Pharmacy Forward is expected to generate approximately $400 million in value by the end of 2028, according to Evernorth.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us